Aerie Pharmaceuticals, Inc. (AERI)
(Delayed Data from NSDQ)
$39.78 USD
+1.23 (3.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.78 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AERI 39.78 +1.23(3.19%)
Will AERI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AERI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AERI
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
AERI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals
Talaris (TALS) Down on Patient Death From Renal Transplant Study